T
Tolerance Bio
Biotech & Life Sciences · Philadelphia, United States · Founded 2023
Innovative therapies enhancing immune tolerance by restoring thymus function to combat immune-mediated diseases MoreLess
Tolerance Bio is at the forefront of developing innovative therapies aimed at enhancing immune tolerance by restoring and preserving the function of the thymus, a critical organ in the immune system. The company targets immune-mediated diseases, which include cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies. These conditions represent significant unmet medical challenges due to abnormalities in immune tolerance. Tolerance Bio operates in the biotechnology sector, focusing on a multi-platform approach to manipulate thymus function, thereby addressing the root causes of these diseases. The business model involves pioneering novel therapeutics with the potential to rapidly advance and validate concepts in rare diseases, followed by proof of concept in broader indications. Revenue is generated through the development and commercialization of these therapeutics, targeting both niche and major markets. The company serves healthcare providers, researchers, and patients seeking advanced solutions for immune-related conditions. Keywords: thymus, immune tolerance, biotechnology, immune-mediated diseases, therapeutics, innovation, Francisco Leon, autoimmunity, transplant rejection, rare diseases.
Company overview
Tolerance Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2023
- Headquarters
- Philadelphia, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 73.7
Valuation & funding
Tolerance Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2026 | $0 | — | NeolmmuneTech | ↗ |
| EARLY VC✓Equity / VC | Jun 2026 | $0 | — | BCI · Beyond Celiac | ↗ |
| SEED✓Equity / VC | Dec 2024 | $20M | $81M | Ben Franklin Technology Partners of Northeastern Pennsylvania · Criteria Bio Ventures · BioAdvance · Pacific 8 Ventures | ↗ |
| SPINOUT✓Other financing | Jan 2023 | $0 | — | University of Colorado Anschutz Medical Campus · University of Florida · University of Colorado | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 17 |
| 2025 | 17 |
| 2024 | 12 |
Growth signals
Tolerance Bio website traffic
Latest recorded traffic for Tolerance Bio is 1.7K monthly website visits, up 13.3% over the last three months. Tolerance Bio's team grew 0% over the past year.
Comparisons
Tolerance Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Tolerance Bio's talent
Source: Dealroom Talent Intelligence.
Investors
12 investors on Tolerance Bio's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Tolerance Bio has talent and traffic
team presence
In the news
Latest news about Tolerance Bio
Recent press, funding announcements, and product moves mentioning Tolerance Bio — open to read from the original sources.
Market sentiment
What the market is saying about Tolerance Bio
An AI-synthesized read of the highest-engagement posts about Tolerance Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tolerance Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.